Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns. 
Via InvestorPlace
Peering Into Horizon Therapeutics's Recent Short Interest
Via Benzinga
Here's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How Is The Market Feeling About Horizon Therapeutics?
Via Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
$1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
On Friday, the U.S. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Is What Whales Are Betting On Horizon Therapeutics
Via Benzinga
Peering Into Horizon Therapeutics's Recent Short Interest
Via Benzinga
P/E Ratio Insights for Horizon Therapeutics
Via Benzinga
Is Amgen Stock a Top Buy and Hold?
The biotech checks several important boxes for long-term shareholders. 
Via The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Tesla unveiled an updated Model 3, but also slashed Model S, X prices. 
Via Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).  
Via Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
The deal can now close in the fourth quarter. 
Via Investor's Business Daily
Is This the Green Light Biotech Stocks Have Been Waiting For?
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics. 
Via The Motley Fool
Nasdaq, S&P 500 Futures Flatline Ahead Of JOLTS, House Price Data; Why This Analyst Recommends 'Buying Weakness Than Selling Rallies'
Via Benzinga
Topics Stocks
Exposures US Equities
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals
Via Benzinga
FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal
The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc (NASDAQ: AMGN), concerning its proposed acquisition of Horizon Therapeutics PLC... 
Via Benzinga
Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle
The FTC is pulling back somewhat on its effort to challenge the deal. 
Via Investor's Business Daily
Could Amgen Stock Help You Become a Millionaire?
Its pending acquisition of Horizon Therapeutics could make the company much bigger. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings
The massive biotech company also beat second-quarter expectations Thursday. 
Via Investor's Business Daily
Amgen To Report Q2 Earnings: Here's What To Expect
Amgen will report second-quarter 2023 results on Aug. 3, after the market close. 
Via Talk Markets
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.